| 111.52 1.38 (1.25%) | 01-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 134.31 | 1-year : | 156.88 |
| Resists | First : | 115 | Second : | 134.31 |
| Pivot price | 101.49  |
|||
| Supports | First : | 102.91 | Second : | 95.44 |
| MAs | MA(5) : | 106.34 |
MA(20) : | 100.28 |
| MA(100) : | 94.2 |
MA(250) : | 98.43  |
|
| MACD | MACD : | 2.5 |
Signal : | 1.3 |
| %K %D | K(14,3) : | 76.6 |
D(3) : | 74.8 |
| RSI | RSI(14): 71.7 |
|||
| 52-week | High : | 128.28 | Low : | 81.36 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RVTY ] has closed It is unclear right now based on current values. 71.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 112.87 - 113.32 | 113.32 - 113.76 |
| Low: | 107.15 - 107.65 | 107.65 - 108.13 |
| Close: | 110.71 - 111.5 | 111.5 - 112.26 |
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Wed, 14 Jan 2026
The Bull Case For Revvity (RVTY) Could Change Following Upbeat 2025 Guidance And New Lilly AI Alliance - Yahoo Finance
Wed, 14 Jan 2026
What's Going On With Revvity Stock Wednesday? - Revvity (NYSE:RVTY) - Benzinga
Tue, 13 Jan 2026
Revvity (NYSE:RVTY) Shares Gap Up - Here's Why - MarketBeat
Tue, 13 Jan 2026
Why Is RVTY Stock Surging in Premarket? Q4 Revenue Outlook Tops Expectations - Tokenist
Mon, 12 Jan 2026
Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance - Business Wire
Mon, 12 Jan 2026
RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models - TradingView — Track All Markets
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 113 (M) |
| Shares Float | 104 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 104.1 (%) |
| Shares Short | 6,140 (K) |
| Shares Short P.Month | 8,200 (K) |
| EPS | 1.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 64.68 |
| Profit Margin | 8.4 % |
| Operating Margin | 13.7 % |
| Return on Assets (ttm) | 2 % |
| Return on Equity (ttm) | 3 % |
| Qtrly Rev. Growth | 2.2 % |
| Gross Profit (p.s.) | 13.67 |
| Sales Per Share | 24.78 |
| EBITDA (p.s.) | 7.27 |
| Qtrly Earnings Growth | -47.5 % |
| Operating Cash Flow | 575 (M) |
| Levered Free Cash Flow | 528 (M) |
| PE Ratio | 57.48 |
| PEG Ratio | 0 |
| Price to Book value | 1.72 |
| Price to Sales | 4.49 |
| Price to Cash Flow | 21.98 |
| Dividend | 0.07 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|